Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Emitters == Several different emitter configurations have been used for FD emitters, such as single tips, sharp blades and thin wires. Single metal tips can be made from etching wires either by periodically dipping them into molten salts or by electrolysis in aqueous solutions. Compared to other emitter types, the single tips have the advantage that they can reach the highest field strengths. In addition, well-defined geometric shape of a single tip allows accurate calculation of the potential distribution in the space between the tip and the counter electrode. For blades used as emitters, their ruggedness under the high electric field is one of their advantages. Different thin wires were also used as emitters, such as platinum wires and tungsten wires. Platinum wires are fragile, and tungsten wires are much more stable than platinum wires. Among those emitters, carbon-microneedles tungsten wires are the most widely used emitters in FD mass spectrometry.
Centers for Disease Control: Obesity Data and Statistics American Obesity Treatment Association: Obesity Education and Statistics Archived February 28, 2021, at the Wayback Machine Contributors to Obesity | Tableau Public Archived January 3, 2015, at the Wayback Machine (infographic for the United States)
Scientific techniques, such as immunostaining, depend on chemical specificity. Immunostaining utilizes the chemical specificity of antibodies in order to detect a protein of interest at the cellular level. Another technique that relies on chemical specificity is Western blotting, which is utilized to detect a certain protein of interest in a tissue. This technique involves gel electrophoresis followed by transferring of the sample onto a membrane which is stained by antibodies. Antibodies are specific to the target protein of interest, and will contain a fluorescent tag signaling the presence of the researcher's protein of interest. Enzyme promiscuity Substrate (chemistry)
{\displaystyle {\begin{array}{l}{}\\{\ce {^{235}_{92}U->[\alpha ][7.04\times 10^{8}\ {\ce {y}}]{^{231}_{90}Th}->[\beta ^{-}][25.52\ {\ce {h}}]{^{231}_{91}Pa}->[\alpha ][3.27\times 10^{4}\ {\ce {y}}]{^{227}_{89}Ac}}}{\begin{Bmatrix}{\ce {->[98.62\%\beta ^{-}][21.772\ {\ce {y}}]{^{227}_{90}Th}->[\alpha ][18.693\ {\ce {d}}]}}\\{\ce {->[1.38\%\alpha ][21.772\ {\ce {y}}]{^{223}_{87}Fr}->[\beta ^{-}][22.00\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{223}_{88}Ra->[\alpha ][11.435\ {\ce {d}}]{^{219}_{86}Rn}}}\\{\ce {^{219}_{86}Rn->[\alpha ][3.96\ {\ce {s}}]{^{215}_{84}Po}->[\alpha ][1.781\ {\ce {ms}}]{^{211}_{82}Pb}->[\beta ^{-}][36.16\ {\ce {min}}]{^{211}_{83}Bi}}}{\begin{Bmatrix}{\ce {->[99.724\%\alpha ][2.14\ {\ce {min}}]{^{207}_{81}Tl}->[\beta ^{-}][4.77\ {\ce {min}}]}}\\{\ce {->[0.276\%\beta ^{-}][2.14\ {\ce {min}}]{^{211}_{84}Po}->[\alpha ][0.516\ {\ce {s}}]}}\end{Bmatrix}}{\ce {^{207}_{82}Pb}}\end{array}}}
Sources: en.wikipedia.org
== Second round proper == The draw for the second round was made on BBC Two on 7 November 2022 by Jermaine Beckford and Mickey Thomas at the Racecourse Ground in Wrexham, and consisted of the 40 winners from the previous round. The round contained one team from the seventh tier, Alvechurch, who defeated EFL League One club Cheltenham Town in the first round.
=== Optical modulator === When the Fermi level of graphene is tuned, its optical absorption can be changed. In 2011, researchers reported the first graphene-based optical modulator. Operating at 1.2 GHz without a temperature controller, this modulator has a broad bandwidth (from 1.3 to 1.6 μm) and small footprint (~25 μm2). A Mach-Zehnder modulator based on a hybrid graphene-silicon waveguide has been demonstrated recently, which can process signals nearly chirp-free. An extinction up to 34.7 dB and a minimum chirp parameter of -0.006 are obtained. Its insertion loss is roughly -1.37 dB.
== Definition == The name amyloid comes from the early mistaken identification by Rudolf Virchow of the substance as starch (amylum in Latin, from Ancient Greek: ἄμυλον, romanized: amylon), based on crude iodine-staining techniques. For a period, the scientific community debated whether or not amyloid deposits are fatty deposits or carbohydrate deposits until it was finally found (in 1859) that they are, in fact, deposits of albumin-like proteinaceous material.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.